Targeted treatments for AML: the revolution
Lymphoid Highlights from BSH 2017
What is the potential of daratumumab in combination therapy for myeloma?
Azacitidine/HDAC inhibitor combination for high risk AML: a promising pilot study
Potential second-line treatment for indolent lymphoma